UnitedHealth Group division calls the action “baseless” and shows “profound misunderstanding” of drug pricing.

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...

The Government is expected to perform a U-turn in the budget by scrapping plans to impose a capital gains tax (CGT) liability ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a ...

Big Shoulders Fund Northwest Indiana Executive Director Dan Kozlowski won a Driving Change Award from Mitch Daniels ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.